Document is current
Any future updates will be listed below
-
Authors
Strauss, Gregory P.
Raugh, Ian M.
Zhang, Luyu
Luther, Lauren
Chapman, Hannah C.
Allen, Daniel N.
Kirkpatrick, Brian
Cohen, Alex S. http://orcid.org/0000-0003-4014-6904
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R21-MH112925)
- License Information
-
More Information
Article History
Received: 6 July 2021
Accepted: 24 February 2022
First Online: 15 April 2022
Competing interests
: G.P.S. and B.K. are original developers of the Brief Negative Symptom Scale (BNSS) and receive royalties and consultation fees from Medavante-ProPhase LLC in connection with commercial use of the BNSS and other professional activities; these fees are donated to the Brain and Behavior Research Foundation. B.K. has received honoraria and travel support from ProPhase LLC for training pharmaceutical company raters on the BNSS, consulting fees and travel support from Genentech/Roche, Minerva Neurosciences, Lundbeck, and ProPhase LLC, consulting fees from anonymized pharmaceutical companies through Decision Resources, Inc, and from an investment capital company through Guideposts, and from Wockhardt Bio AG for consulting on a legal issue. G.P.S. has consulted for Minerva Neurosciences, Acadia, Otsuka, Boeringher-Ingelheim, and Lundbeck. GPS, BK, and ASC are cofounders of Quantic Innovations LLC that provides resources for digital phenotyping data collection, analysis, and interpretation. All other authors have no conflicts to report.
